Edition:
United States

PDL BioPharma Inc (PDLI.OQ)

PDLI.OQ on NASDAQ Stock Exchange Global Select Market

2.93USD
23 Apr 2018
Change (% chg)

$0.03 (+1.03%)
Prev Close
$2.90
Open
$2.91
Day's High
$2.95
Day's Low
$2.86
Volume
215,978
Avg. Vol
397,790
52-wk High
$3.55
52-wk Low
$2.05

Select another date:

Mon, Apr 9 2018

BRIEF-PDL Biopharma Shareholder, Sevensaoi Capital, Comments On The Nomination Of Shlomo Yanai To PDL Board

* PDL BIOPHARMA SHAREHOLDER, SEVENSAOI CAPITAL, COMMENTS ON THE NOMINATION OF SHLOMO YANAI TO THE PDL BOARD OF DIRECTORS AND DELIVERS LETTER TO THE BOARD OUTLINING SIGNIFICANT CONCERNS

BRIEF-PDL Biopharma Announces Q4 Revenue Of $68 Million

* PDL BIOPHARMA ANNOUNCES FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS

BRIEF-PDL Biopharma Terminates Interest In Pursuing Acquisition Of Neos

* PDL BIOPHARMA TERMINATES INTEREST IN PURSUING ACQUISITION OF NEOS

BRIEF-PDL Biopharma Inc files for non-timely 10-Q

* PDL Biopharma Inc files for non-timely 10-Q - SEC filing‍​ Source text: (http://bit.ly/2AC3Kyu) Further company coverage:

BRIEF-PDL Biopharma urges Neos Therapeutics to provide update on sale process

* PDL Biopharma's proposal to acquire Neos Therapeutics expires today; PDL urges Neos to provide update on sale process

BRIEF-PDL Biopharma Inc reports Q3 revenue $62.7 million

* PDL Biopharma Inc announces third quarter 2017 financial results

Neos Therapeutics to consider other offers after PDL snub: sources

U.S. drugmaker Neos Therapeutics Inc , which this week rejected a fourth takeover offer by PDL Biopharma Inc , will consider offers from other potential buyers, according to people familiar with the matter.

CORRECTED-Neos Therapeutics to consider other offers after PDL snub -sources

Oct 31 U.S. drugmaker Neos Therapeutics Inc , which this week rejected a fourth takeover offer by PDL Biopharma Inc, will consider offers from other potential buyers, according to people familiar with the matter.

BRIEF-PDL Biopharma issues response to Neos Therapeutics rejection of PDL acquisition proposal

* PDL Biopharma issues statement in response to Neos Therapeutics rejection of PDL acquisition proposal

BRIEF-PDL Biopharma announces settlement agreement with Valeant

* PDL Biopharma - ‍Valeant to pay a one-time, lump-sum payment of $13.0 million as part of settlement

Select another date: